The Cytotoxicity Effect of Curcumin Loaded Folic Acid Conjugated-Nanoparticles on Breast Cancer Cells and Its Association with Inhibition of STAT3 Phosphorylation

Doxorubicin-loaded pH-responsive porphyrin-derived carbon dots as a promising biocompatible drug delivery system for effective chemotherapy of breast cancer

Doxorubicin (DOX), a widely used chemotherapy drug for breast cancer, suffers from limitations such as non-specific toxicity and drug resistance. To address these challenges, we developed a novel drug delivery system (DDS) using porphyrin-derived carbon dots (CDs) as carriers for DOX. Porphyrin-based CDs were synthesized solvothermally from tetrakis(4-carboxyphenyl) porphyrin (TCPP) and urea. DOX was non-covalently loaded onto the CDs to form the DOX@CDs nanocomposite. The resulting CDs exhibited desirable properties like excellent water solubility, stability, and biocompatibility. Moreover, the DOX@CDs complex showed a high drug loading efficiency of 93% and a pH-responsive release profile, with enhanced release at acidic tumor microenvironments. The DOX@CDs nanocomposite demonstrated significantly improved cytotoxicity against human breast cancer MCF-7 and MDA-MB-231 cell lines (at IC50 values 24.08 ± 1.446 and 10.587 ± 0.815 μg mL-1) compared to free DOX (at IC50 values = 262.96 ± 1.807 and 261.6 ± 0.907 μg mL-1). Analysis by fluorescence microscopy and flow cytometry demonstrated that the enhanced cytotoxicity of the DOX@CDs complex compared to free DOX correlated with its greater cellular uptake and localization in cancerous cells. Notably, the nanocomposite exhibited reduced hemolytic activity, indicating enhanced biocompatibility. Our findings suggest that porphyrin-derived CDs hold promise as a safe and effective nanocarrier for targeted DOX delivery, offering a potential strategy to improve the therapeutic efficacy of breast cancer chemotherapy.

Development of Graphene Oxide-Based Anticancer Drug Combination Functionalized with Folic Acid as Nanocarrier for Targeted Delivery of Methotrexate

Graphene has become a prominent material in cancer research in recent years. Graphene and its derivatives also attract attention as carriers in drug delivery systems. In this study, we designed a graphene oxide (GO)-based methotrexate (MTX)-loaded and folic acid (FA)-linked drug delivery system. MTX and FA were bound to GO synthesized from graphite. MTX/FA/GO drug delivery system and system components were characterized using Fourier transform infrared spectroscopy (FTIR), differential calorimetric analysis (DSC), scanning electron microscopy (SEM), transmission electron microscopy (TEM), zeta potential analysis, and dimension measurement (DLS) studies. SEM and TEM images confirmed the nanosheet structure of GO synthesized from graphite, and it was shown that MTX/FA binding to GO transformed the two-dimensional GO into a three-dimensional structure. FTIR and DSC graphs confirmed that oxygen atoms were bound to GO with the formation of carboxylic, hydroxyl, epoxide, and carbonyl groups as a result of the oxidation of graphite, and GO was successfully synthesized. Additionally, these analyses showed that MTX and FA bind physicochemically to the structure of GO. The in vitro Franz diffusion test was performed as a release kinetic test. The release kinetics mathematical model and correlation coefficient (R2) of MTX-loaded GO/FA nanomaterials were found to be the Higuchi model and 0.9785, respectively. Stiffness analyses showed that adding FA to this release system facilitated the entry of the drug into the cell by directing the system to target cells. As a result of the stiffness analyses, the stiffness values of the control cell group, free MTX, and MTX/FA/GO applied cells were measured as 2.34 kPa, 1.87 kPa, and 1.56 kPa, respectively. According to these results, it was seen that MTX/FA/GO weakened the cancer cells. Combined use of the MTX/FA/GO drug delivery system had a higher cytotoxic effect than free MTX on the MDA-MB-231 breast cancer cell line. The results showed that the synthesized MTX/FA/GO material has promising potential in cancer cell-specific targeted therapy for MTX as a drug delivery system.

Curcumin Loaded onto Folic acid Carbon dots as a Potent drug Delivery System for Antibacterial and Anticancer Applications

Numerous malignancies have been shown to be successfully treated with Curcumin. Despite its promising effects, Curcumin has limitations in clinical studies because of its stability, low water solubility, and adsorption. Carbon quantum dots with high biocompatibility can be employed as nanostructured material carriers to enhance Curcumin availability. In this study, folic acid was used as the raw material for the hydrothermal preparation of carbon dots, followed by the loading of Curcumin onto the carbon dots to form a folic acid carbon dot/Curcumin nanocomposite. The morphology and the chemical structure of the synthesized carbon dots were investigated. Folic acid carbon dots displayed robust emission peaks with a quantum yield of 41.8%. Moreover, the adsorption effectiveness of Curcumin on carbon dots was determined to be 83.11%. The liberating pattern of Curcumin was pH-dependent and reached 36 and 27% after a few hours at pH 5 and 7.4, respectively. The release occurs via the Fickiann diffusion mechanism with ah n value less than 0.45.The nanocomposite was tested for antibacterial activity against gram-negative Pseudomonas aeruginosa ATCC 27,853 and gram-positive Staphylococcus aureus ATCC 25,923. The nanocomposite displayed antibacterial behavior with MIC 12.5 µg/mL. The anticancer activities of the nanocomposite were further tested against high-folate receptor-expressing Hela cells (cervical malignancy) and low-folate receptor-expressing HepG2 cells (hepatocellular carcinoma). Folic acid carbon dot/Curcumin nanocomposite reduced Hela cell viability at an IC50 of 88.723 ± 0.534 g/mL. On the other hand, HepG2 cells showed no toxicity response.

Application of curcumin nanoformulations to target folic acid receptor in cancer: Recent trends and advances

Curcumin, derived from turmeric, has a strong anticancer potential known for millennia. The development of this phytochemical as a medicine has been hampered by several significant deficiencies, including its poor water solubility and low bioavailability. This review article discusses possibilities to overcome these bottlenecks by focusing on this natural polyphenol's nanoformulation. Moreover, preparation of curcumin conjugates containing folates as ligands for folic acid receptors can add a new important dimension in this field, allowing specific targeting of cancer cells, considering the significantly higher expression of these receptors in malignant tissues compared to normal cells. It is highly expected that simultaneous improvement of different aspects of curcumin in fighting against such a complex and multifaceted disease like cancer. Therefore, we can better comprehend cancer biology by developing a mechanistic understanding of curcumin, which will also inspire the scientific community to develop new pharmacological models, and exploration of emerging directions to revitalize application of natural products in cancer therapy.

Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors

INTRODUCTION

Breast cancer (BC) accounts for the majority of cancers among the female population. Anomalous activation of various signaling pathways has become an issue of concern. The JAK-STAT signaling pathway is activated in numerous cancers, including BC. STAT3 is widely involved in BCs, as 40 % of BCs display phosphorylated STAT3. JAK-STAT signaling is crucial for proliferation, survival, metastasis and other cellular events associated with the tumor microenvironment. Hence, targeting this pathway has become an area of interest among researchers.

KEY FINDINGS

This review article focuses on the role of STAT3 in the initiation, proliferation, progression and metastasis of BC. The roles of various phytochemicals, synthetic molecules and biologicals against JAK-STAT and STAT3 in various cancers have been discussed, with special emphasis on BC.

SIGNIFICANCE

JAK and STAT3 are involved in various phases from initiation to metastasis, and targeting this pathway is a promising approach to inhibit the various stages of BC development and to prevent metastasis. A number of phytochemicals and synthetic and biological molecules have demonstrated potential inhibitory effects on JAK and STAT3, thereby paving the way for the development of better therapeutics against BC.